MindMed has high hopes for its new LSD-based anxiety therapy.
MindMed has high hopes for its new LSD-based anxiety therapy.
Numinus adds to its management team.
MindMed's Microdosing Division is expanding its ADHD clinical trial.
Certain shareholders have agreed to a voluntary resale restriction that covers 17.8 million shares.
Newly-listed Numinus Wellness provides a corporate update.
MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.
Psychedelic drug proponents have touted some very exciting clinical studies. Investors will want to look past the headlines and take a closer look at these drug therapies.
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community.
MindMed has issued 24.95 million units at a unit price of CAD$0.53.
Champignon Brands' new Director has extensive mental health credentials.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now